Financial Performance - The company reported nominal revenues and a net loss of $6,278,191 for the year ended December 31, 2025, compared to a net loss of $1,517,431 for the year ended December 31, 2024[20]. - The company has a working capital deficiency, raising substantial doubt about its ability to continue as a going concern[113]. - The company has identified material weaknesses in its internal controls over financial reporting, which could lead to inaccurate financial statements and negatively affect stock price[209]. - The company does not intend to pay dividends for the foreseeable future, opting to retain earnings for business operations and expansion[204]. Market Opportunities - The global phototherapy treatment market is projected to rise from approximately $1.9 billion in 2023 to around $3.23 billion by 2033, with a CAGR of about 5.2% during the forecast period[24]. - The Indian phototherapy treatment market is expected to grow at an estimated CAGR of approximately 7.8% as of 2023, driven by increasing prevalence of skin disorders and improved healthcare access[24]. - The global psoriasis treatment market was valued at approximately $34 billion in the 12 months ending June 2023, with the US accounting for about 78% of total sales and growing at a CAGR of approximately 18%[25]. - Management believes that the prevalence of psoriasis in India ranges from 0.44% to 2.8% of the population, indicating significant market opportunity[26]. - The global vitiligo treatment market was valued at around $538.90 million in 2024, projected to grow at a CAGR of 4.60% from 2025 to 2034, reaching approximately $807.70 million by 2034[27]. Product Development and Launches - The Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels[33]. - CB-101, a treatment for atopic dermatitis, is planned for reformulation and expected to be available online in the US in Q2 2026[36]. - NoStingz, a sunscreen product, is planned for reformulation and will comply with FDA guidelines, though a launch timeline has not yet been established[37]. - The Hair Enzyme Booster (JW-700) is expected to launch in the US in Q4 2024 and is designed to enhance the efficacy of minoxidil[35]. - The Hair Enzyme Booster (JW-700) has undergone multiple clinical trials, demonstrating its potential efficacy in treating androgenetic alopecia[35]. Regulatory Compliance and Challenges - Regulatory compliance is critical, with products subject to FDA regulations for both OTC and cosmetic products, which include safety, labeling, and manufacturing standards[90][91]. - The Hair Enzyme Booster received CDSCO cosmetic labeling approval in June 2023, demonstrating compliance with Indian regulatory standards for cosmetics[97]. - Regulatory approvals are critical for the company's products, and delays or difficulties in clinical trials may hinder future commercialization[131]. - The company must develop and introduce new products to remain competitive, as the industry is subject to rapid change[125]. - The company does not have any products on the market that have been approved by the FDA for the treatment of disease, which limits its market potential[130]. Competition and Market Position - The company faces competition from larger firms with more resources, which may impact its ability to maintain market share and respond to regulatory changes[81][82]. - The company faces intense competition in the skin care and hair growth product markets, with competitors having greater financial and technical resources[117]. - The U.S. psoriasis market is dominated by biologics, with IL-23 inhibitors holding approximately 31% market share, followed by IL-17 inhibitors at 23%, TNF inhibitors at 23%, and ustekinumab at 13%[83]. Strategic Partnerships and Licensing - Caring Brands has licensed minoxidil products to Taisho, a company with $2.6 billion in revenue, with milestone payments of up to $200,000 and a 3% royalty[35]. - The Cosmofix/San Pellegrino license agreement grants exclusive rights to manufacture and distribute Photocil and Hair Enzyme Booster (JW-700) in India and 31 other territories, with an upfront fee of $20,000 and minimum annual royalties of $50,000 starting from the second year[63][75]. - The agreement with Taisho Pharmaceutical Co., Ltd. includes a $200,000 upfront payment and a 3% royalty on net sales for the Hair Enzyme Booster (JW-700) in Japan, with the first regulatory authorization milestone payment of $100,000 yet to be achieved[67]. Operational and Management Structure - The company has three full-time employees, including the CEO, operations manager, and executive chairman, indicating a lean operational structure[101]. - The company began providing most administrative services in-house during the year ended December 31, 2024, which may affect future performance as a separate publicly traded entity[167]. - The company has limited experience in managing public company operations, which may lead to additional costs and affect financial performance[198]. Risks and Uncertainties - The company may face challenges in manufacturing products in sufficient quantities or quality, which could hinder development and market demand[144]. - Delays in regulatory filings or adverse developments with regulatory authorities, such as the FDA, could significantly impact the company's financial condition[138]. - Adverse publicity regarding the company's products could significantly affect public perception and sales[128]. - The company may seek additional capital through various means, which could dilute existing stockholders' ownership and impose operational restrictions[172]. Market Strategy and Future Plans - The company plans to enhance its online presence and marketing strategies, with a focus on e-commerce before expanding into traditional retail channels[77]. - The company anticipates that each brand will have its own dedicated e-commerce website to enhance retail sales and brand-specific information[79]. - The company is exploring acquisition opportunities in the branded consumer products space, particularly OTC/cosmetic therapeutic brands that do not require additional FDA approval[78].
Caring Brands(CABR) - 2025 Q4 - Annual Report